News | January 27, 2023
Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Asthma patients are more likely to have an asthma attack during winter
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
Subscribe To Our Newsletter & Stay Updated
